NL-OMON46997招募中2 期
Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY) - COWBOY
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •In order to participate in this study, a subject must meet all of the following criteria:;• Adults 18 years and older ;• World Health Organization (WHO) Performance Status 0-2;• Histologically or cytologically confirmed Stage IV, or unresectable stage III, BRAF V600E/K mutated melanoma;• Measurable disease according to RECIST 1.1;• Signed and dated informed consent form;• No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1;• No prior BRAFi and/ or MEKi therapy;• No immunosuppressive medications;• Screening laboratory values must meet the following criteria and should be obtained within 10 days prior to randomization:;o WBC >= 2.0x109/L, Neutrophils >= 1.0x109/L, Platelets >= 100 x109/L, Hemoglobin >= 5.0mmol/L;o Creatinine <= 2x ULN;o AST, ALT <= 2.5 x ULN (<=5 x ULN for patients with liver metastases);o Bilirubin <=2 X ULN;o LDH > ULN, < 5x ULN;• No symptomatic brain metastases (asysmptomatic brain metastases, accidentally found during screening can be included) ;• No leptomeningeal metastases;• No active autoimmune disease requiring systemic treatment in the past 3 months or a documented history of autoimmune disease, or history of syndrome that required systemic steroids, at daily dose of >=10mg prednisone or equivalent, or immunosuppressive medications. (Subjects with vitiligo or resolved childhood asthma/atopy are excluded from this rule (and will not be excluded from this study). Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen*s syndrome will not be excluded from the study.);• No evidence of interstitial lung disease or active, non-infectious pneumonitis;• No active infection requiring therapy;• No known additional malignancy that is progressing or requires active treatment;• Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days + the time required for nivolumab to undergo five half-lives) after the last dose of study medication;• WOBCP must have a negative serum or urine pregnancy test within 96 hours prior to the start of study treatment and must not be breast feeding;• Men must agree to the use of male contraception during the study treatment period and for at least 31 weeks after the last dose of study drug.;• Currently not participating in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.;• No underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events
排除标准
- •Not applicable
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY)EUCTR2016-003279-23-NLRadboudumc200
已完成
2 期
Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY)skin cancerMelanomaNL-OMON48120Radboud Universitair Medisch Centrum200
进行中（未招募）
1 期
Evaluate the safety and the efficacy of Vemurafenib/PEG-interferon in melanoma patientsEvaluate the safety and the efficacy of Vemurafenib/PEG-interferon combination and the IFNAR1 upregulation lead by this treatment in advanced melanoma patients harboring the V600BRAF mutationMedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2013-003730-33-ITFondazione Melanoma ONLUS48
进行中（未招募）
1 期
Clinical Trial to evaluate the efficacy of vemurafenib in combination with cobimetinib (continuous and intermittent) in BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma.BRAFV600-mutation positive patients with unresectable locally advanced or metastatic melanoma.MedDRA version: 17.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864EUCTR2014-005277-36-ESGrupo Español Multidisciplicinar de Melanoma (GEM)116
进行中（未招募）
1 期
A phase II trial of vemurafenib plus cobimetinib in patients treated with prior first-line systemic immunotherapy for inoperable locally advanced or metastatic melanomaPatients with advanced melanoma who have received one prior immunotherapy systemic regimen for advanced disease, for whom vemurafenib/cobimetinib treatment has been scheduled by the treating physician.MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2017-000504-20-ITFONDAZIONE MELANOMA ONLUS62